Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Luke Maese,Mignon L Loh,Mi Rim Choi,Tong Lin,Etsuko Aoki,Michelle Zanette,Shirali Agarwal,Robert Iannone,Jeffrey A Silverman,Lewis B Silverman,Elizabeth A Raetz,Rachel E Rau

Blood（2023）

引用 9|浏览29

暂无评分

摘要

•Intramuscular JZP458 at 25/25/50 mg/m2 M/W/F was effective in patients with ALL/LBL, with a safety profile similar to other asparaginases.•JZP458 overcomes one of the most significant drug shortage issues facing patients with ALL/LBL.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要